BioCentury
ARTICLE | Company News

Ionis, Ribo in China partnership

April 18, 2017 10:23 PM UTC

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said it granted Suzhou Ribo Life Science Co. Ltd. (Kushan, China) Chinese commercialization rights to two antisense drug candidates in metabolic disease and cancer, with an option for a third candidate. Ionis received an undisclosed upfront payment and equity stake in Ribo. Ionis declined to name the candidates or discuss financial terms, and Ribo did not respond to inquiries in time for publication.

Ribo will also conduct a program to discover and identify candidates using Ionis' single-stranded RNAi technology. Ribo may opt to obtain local rights to each candidate, and would be responsible for development and commercialization. Ionis is eligible for milestones and royalties...